HBV (Hepatitis B Virus)
10
2
2
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (10)
HIV/HBV/HCV Triple Screening in Primary Care
MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo
Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure
Hepatitis B and C Within the Chinese Community in Milan
Immune Dynamics in the Natural History of Chronic HBV Infection
Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy
Occult Hepatitis B Virus Infection and HBV Reactivation After Switching to Long Acting Therapy in Patients With HIV-1
Study of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid
Lamivudine and Adefovir to Treat Chronic Hepatitis B